Samumed Announces Presentation of Clinical Data Analysis on SM04690 for Treatment of Knee Osteoarthritis at International Workshop on Osteoarthritis Imaging (IWOAI) 2018 Conference
June 29, 2018 08:00 ET
|
SAMUMED
SAN DIEGO, June 29, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present an analysis of phase 2 clinical data on SM04690 for the treatment of knee osteoarthritis (OA) as a...
Samumed Presents Clinical and Preclinical Data at European League Against Rheumatism (EULAR) 2018 Annual Congress
June 20, 2018 08:00 ET
|
SAMUMED
Phase 2 data in osteoarthritis and preclinical data in tendinopathy and psoriasis demonstrated the emerging breadth of the Samumed pipeline in arthritis related diseases and in dermatology SAN DIEGO,...
Samumed Announces Multiple Presentations at the European League Against Rheumatism (EULAR) 2018 Annual Congress
June 08, 2018 08:00 ET
|
SAMUMED
SAN DIEGO, June 08, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present clinical and preclinical data on two of the company’s investigational drugs, SM04690, for the...
Samumed to Present Data on Multiple Product Candidates in Five Presentations at The Orthobiologic Institute (TOBI) 2018 Annual Symposium
May 31, 2018 08:00 ET
|
SAMUMED
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt signaling pathway research and development, today announced that it will present clinical and pre-clinical data on its small...
Samumed Announces Presentation at the 2018 American Thoracic Society (ATS) International Conference
May 11, 2018 08:00 ET
|
SAMUMED
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt signaling pathway research and development, today announced it will present preclinical data on the company’s...
Samumed Presented Multiple Abstracts Supporting Potential Disease Modification at the Osteoarthritis Research Society International (OARSI) 2018 World Congress
May 07, 2018 08:00 ET
|
SAMUMED
SAN DIEGO, May 07, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt research and development, presented its most recent clinical and preclinical data for two of the company’s investigational...
Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society International (OARSI) World Congress
April 23, 2018 14:00 ET
|
SAMUMED
SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt research and development, today announced it will present its most recent clinical and preclinical data on the company’s...
Samumed Doses First Patient in Phase 1 Trial of SM04690 for Treatment of Degenerative Disc Disease
December 18, 2017 08:00 ET
|
SAMUMED
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first degenerative disc disease (DDD) patient in its Phase 1 trial of SM04690, a small molecule Wnt...
Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors
December 11, 2017 08:00 ET
|
SAMUMED
SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small molecule Wnt pathway inhibitor in oral...
Samumed Announces Results of Phase 2 Trial of SM04690 Demonstrating Evidence of Cartilage Regeneration in Patients with Knee Osteoarthritis
November 06, 2017 08:00 ET
|
SAMUMED
- Data support potential of SM04690 as a disease modifying drug for knee osteoarthritis - SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced detailed results from the Phase...